Prudential Financial
APGE

Prudential Financial’s Apogee Therapeutics APGE Stock Holding History

Prudential Financial’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
76,620
+12,720
+20% +$1.15M 0.01% 690
2026
Q1 		$5.38M Buy
63,900
+9,600
+18% +$697K 0.01% 895
2025
Q4 		$4.1M Buy
54,300
+41,440
+322% +$2.61M ﹤0.01% 1004
2025
Q3 		$511K Sell
12,860
-55,985
-81% -$2.14M ﹤0.01% 1945
2025
Q2 		$2.99M Buy
68,845
+43,940
+176% +$1.67M ﹤0.01% 1188
2025
Q1 		$930K Buy
24,905
+370
+2% +$14.3K ﹤0.01% 1604
2024
Q4 		$1.11M Hold
24,535
– – ﹤0.01% 1536
2024
Q3 		$1.44M Buy
24,535
+55
+0.2% +$2.63K ﹤0.01% 1694
2024
Q2 		$963K Buy
24,480
+17,715
+262% +$860K ﹤0.01% 1852
2024
Q1 		$450K Buy
+6,765
New +$295K ﹤0.01% 2210

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Prudential Financial's APGE Position: Q2 2026 in Review

Prudential Financial increased its Apogee Therapeutics (APGE) stake by 20% in Q2 2026, buying an estimated $1.15M and bringing the position to 76,620 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #690.

Prudential Financial first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Prudential Financial held 76,620 shares of Apogee Therapeutics worth $10.2M as of Q2 2026.
  • Prudential Financial bought 12,720 Apogee Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Apogee Therapeutics made up 0.01% of Prudential Financial's portfolio in Q2 2026, its #690 holding.
  • Prudential Financial first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.